S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

• Ryan Jacobs,
• Ranjit Nair,
• Seok-Goo Cho,
• Sumana Devata,
• Sameh Gaballa,
• Dok Hyun Yoon,
• Don Stevens,
• Jin Seok Kim,
• Nirav N Shah,
• Denise Marie Brennan,
• Jason Law,
• Robin Lesley,
• Rob Chen,
• Alessandra Forcina,
• Ben Buelow,
• Jing-Zhou Hou

Affiliations

Ryan Jacobs

1 Atrium Health Levine Cancer Institute, Charlotte, United States

Ranjit Nair

2 The University of Texas MD Anderson Cancer Center, Houston, United States

Seok-Goo Cho

3 Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Rep. of South

Sumana Devata

4 Medical College of Wisconsin, Milwaukee, United States

Sameh Gaballa

5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States

Dok Hyun Yoon

6 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Rep. of South

Don Stevens

7 Norton Cancer Institute, Norton Health Care, Louisville, United States

Jin Seok Kim

8 Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Rep. of South

Nirav N Shah

4 Medical College of Wisconsin, Milwaukee, United States

Denise Marie Brennan

9 AstraZeneca, Waltham, United States

Jason Law

9 AstraZeneca, Waltham, United States

Robin Lesley

10 AstraZeneca, South San Francisco, United States

Rob Chen

11 AstraZeneca, Cambridge, United Kingdom

Alessandra Forcina

11 AstraZeneca, Cambridge, United Kingdom

Ben Buelow

12 Ancora Biotech, Inc., Palo Alto, United States

Jing-Zhou Hou

13 Lemieux Center for Blood Cancers, UPMC Hillman Cancer Center, Pittsburgh, United States